



07-23-01

RECEIVED  
JUL 26 2001  
TECH CENTER 1600/2900

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Gale *et al.*§  
§  
§  
§  
§  
§  
§  
§  
§  
§  
§Examiner: Joseph K. McKane and R. Gerstl  
(in parent application)

Serial No.: 09/838,998

Group Art Unit: 1626

Filed: April 20, 2001

Atty. Dkt. No.: 045404.0002

For: CALIXPYRROLES,  
CALIXPYRIDINOPYRROLES  
AND CALIXPYRIDINES

Express Mail Label: EJ756351449US

Customer No.: 020790

Commissioner for Patents  
Washington, D.C. 20231TRANSMITTAL LETTER

Dear Sir:

With regard to the above-identified application, enclosed please find:

1. Information Disclosure Statement;
2. Form PTO-1449 (14 pages);
3. Copy of references A1 - A2, C81 and C84 - C86; and
4. return postcard. Please date stamp and mail the return postcard.

No fees are believed to be due with the filing of this Information Disclosure Statement. However, if fees are deemed necessary, the Commissioner is authorized to charge said fees to Akin, Gump, Strauss, Hauer & Feld, L.L.P., Deposit Account No. 01-0660.


Respectfully Submitted,

Date: July 20, 2001

By: Gloria L. Norberg

Reg. No.: 36,706

Agent for Applicants



JUL 26 2001

RECEIVED

In re Application of:  
Gale *et al.*

§ Examiner: Joseph K. McKane and R. Gerstl  
§ (in parent application)

Serial No.: 09/838,998

§  
§ Group Art Unit: 1626

Filed: April 20, 2001

§  
§  
§ Atty. Dkt. No.: 045404.0002

For: CALIXPYRROLES,  
CALIXPYRIDINOPYRROLES  
AND CALIXPYRIDINES

Express Mail Label: EJ756351449US

Customer No.: 020790

Commissioner for Patents  
Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 CFR §§1.56, 1.97 and 1.98, record is being made below of documents which the Patent Office is requested to consider in connection with examination of the above-identified patent application.

As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 CFR §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind and specifically is not an admission that the documents listed on attached Form PTO-1449 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 CFR §1.56(b).

The present application is a divisional application of then copending USSN 08/833,379, filed April 4, 1997, now U.S. 6,262,257, to which the present application claims priority for an earlier effective filing date under §120. Accordingly, copies of references provided in priority case USSN 08/833,379 are not provided; however, copies of references A1 - A2, C81, and C84 - C86 are provided.


Reference C4 is in German and relates to a condensation product of pyrrole with acetone. Reference C22 is in German and relates to the effect of acetone on pyrrole. Reference C52 is in German and relates to a porphyrinogen with a 1,8-diphenylanthracene bridge.

It is respectfully requested that the documents be carefully considered by the Examiner and made of record in the case. It is also requested that the Examiner initial the PTO-1449 Form and return a copy of the initialed form to Applicant's agent, Dr. Gloria L. Norberg.

The present Information Disclosure Statement is believed to be timely filed in accordance with 37 C.F.R. §1.97(b)(1). No fees are believed to be due in connection with the filing of this Information Disclosure Statement; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fee from Akin, Gump, Strauss, Hauer & Feld, L.L.P. Deposit Account No.01-0660.

Date: July 20, 2001

Akin, Gump, Strauss, Hauer & Feld, L.L.P.  
816 Congress Avenue, Suite 1900  
Austin, Texas 78701  
(512) 499-6200

Respectfully submitted,  
By   
Gloria L. Norberg  
Agent for Applicant(s)  
Registration No. 36,706